Whole-genome sequencing identifies recurrent mutations in chronic lymphocytic leukaemiaXosé S. Puente, Simon Heath, Magda Pinyol et al.|Nature|2011Cited by 1.5k
MYC/BCL2 protein coexpression contributes to the inferior survival of activated B-cell subtype of diffuse large B-cell lymphoma and demonstrates high-risk gene expression signatures: a report from The International DLBCL Rituximab-CHOP Consortium ProgramShimin Hu, Ken H. Young, Santiago Montes‐Moreno et al.|Blood|2013Cited by 677
Mutational profile and prognostic significance of TP53 in diffuse large B-cell lymphoma patients treated with R-CHOP: report from an International DLBCL Rituximab-CHOP Consortium Program StudyZijun Y. Xu‐Monette, Ken H. Young, Lin Wu et al.|Blood|2012Cited by 390
CD30 expression defines a novel subgroup of diffuse large B-cell lymphoma with favorable prognosis and distinct gene expression signature: a report from the International DLBCL Rituximab-CHOP Consortium Program StudyShimin Hu, Ken H. Young, Zijun Y. Xu‐Monette et al.|Blood|2013Cited by 246
Patients with diffuse large B-cell lymphoma of germinal center origin with BCL2 translocations have poor outcome, irrespective of MYC status: a report from an International DLBCL rituximab-CHOP Consortium Program StudyCarlo Visco, Ken H. Young, Alexandar Tzankov et al.|Haematologica|2012Cited by 165